This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

ASCO, CHICAGO, IL, USA, 31 May-4 JUNE 2019

Afatinib versus methotrexate as second-line treatment for patients with R/M HNSCC progressing on or after platinum-based therapy: LUX-Head & Neck 3 phase III trial

Ye Guo, Myung-Ju Ahn, Anthony Chan, Cheng-Hsu Wang, Jin Hyoung Kang, Sung-Bae Kim, Maximino Bello III, Rajendra Singh Arora, Qingyuan Zhang, Xiaohui He, Ping Li, Arunee Dechaphunkul, Vijay Kumar, Krishna Kamble, Wie Li, Alaa Kandil, Ezra Cohen, Yuan Geng

Related Materials

Learn more about the science behind this poster in the videos, papers and other materials below.

Head and Neck  Squamous Cell Carcinoma  (HNSCC)

Slide Set
BI - Medical Education